For where these oral and higher-dose options sit among the candidates now in development, see the 2026 GLP-1 clinical pipeline, part of the broader GLP-1 and metabolic disease picture
The chronic inflammation cycle has been broken
Glycemic Control A1C reduction Dual incretin response FDA T2D label Weight Loss Secondary benefit Off-label use Doctor-determined Cardiometabolic Better lipid panel Lower BP signals Improved insulin Appetite Control Slows digestion Reduces cravings Dual incretin Manage type 2 diabetes with FDA-approved tirzepatide
Patients who subscribe to Noom Med get access to the full Noom app experience - including daily lessons, food logging, coaching, and community features - alongside their GLP-1 medication and clinical care
do not split, crush, or chew
A pharmaceutical intermediate is an organic compound produced during steps in the synthesis of an API